Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the live video webcast, which is scheduled to begin at 12 p.m. EST, CEO John Climaco will … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a highly accomplished biopharmaceutical industry executive, will join the company’s board effective upon … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has completed enrollment in its global potentially pivotal study evaluating Berubicin. According to the announcement, the study has enrolled 247 patients across 46 clinical trial sites in the United States, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced a recommendation from the independent Data Safety Monitoring Board (“DSMB”) regarding Berubicin, the company’s investigational agent. According to the announcement, the DSMB recommends that CNS Pharmaceuticals’ ongoing global, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification”